710 related articles for article (PubMed ID: 33894623)
1. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
2. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies.
Sousa-Pimenta M; Martins Â; Machado V
Int Rev Cell Mol Biol; 2023; 379():189-219. PubMed ID: 37541724
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.
Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
6. Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles.
Jiang Y; Xia B; Zhang Y; Xu W
Curr Gene Ther; 2017; 16(6):390-400. PubMed ID: 28215147
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.
Innao V; Rizzo V; Allegra AG; Musolino C; Allegra A
Curr Oncol; 2020 Dec; 28(1):159-183. PubMed ID: 33704184
[TBL] [Abstract][Full Text] [Related]
9. Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies.
Ekeke CN; Russell KL; Joubert K; Bartlett DL; Luketich JD; Soloff AC; Guo ZS; Lotze MT; Dhupar R
Ann Surg Oncol; 2021 May; 28(5):2715-2727. PubMed ID: 33575873
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
11. Combination of virotherapy and T-cell therapy: arming oncolytic virus with T-cell engagers.
Song XT
Discov Med; 2013 Dec; 16(90):261-6. PubMed ID: 24333405
[TBL] [Abstract][Full Text] [Related]
12. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
13. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
McGrath K; Dotti G
Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
[TBL] [Abstract][Full Text] [Related]
14. Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies.
Gao X; Liu J; Sun R; Zhang J; Cao X; Zhang Y; Zhao M
Ann Hematol; 2023 Oct; ():. PubMed ID: 37853078
[TBL] [Abstract][Full Text] [Related]
15. A promising future in cancer immunotherapy: Oncolytic viruses.
Seyed-Khorrami SM; Azadi A; Rastegarvand N; Habibian A; Soleimanjahi H; Łos MJ
Eur J Pharmacol; 2023 Dec; 960():176063. PubMed ID: 37797673
[TBL] [Abstract][Full Text] [Related]
16. Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.
Romano G; Marino IR
Drugs Today (Barc); 2019 Feb; 55(2):117-130. PubMed ID: 30816886
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Immunotherapy.
Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
19. Gene and virotherapy for hematological malignancies.
Domingo-Musibay E; Yamamoto M
Int J Hematol; 2016 Jul; 104(1):29-41. PubMed ID: 27289361
[TBL] [Abstract][Full Text] [Related]
20. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
